Physician profile
Manuela Sandoval
NPI 1093350589
$3,557.39
in general payments reported to CMS, 2019-2025
20 companies · $697 in 2025
The $697 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $633 · 2022: $833 · 2023: $887 · 2024: $508 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,091.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $715.27 | 2021-2023 | |
| Glaxosmithkline, LLC. | $664.69 | 2021-2023 | Arexvy, Bexsero, Nucala |
| Genzyme Corporation | $346.59 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $311.26 | 2021-2022 | |
| Inspire Medical Systems, INC. | $272.04 | 2024-2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $127.04 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $124.80 | 2025 | Zoryve |
| Gilead Sciences, INC. | $116.15 | 2025 | Epclusa |
| Axsome Therapeutics, INC. | $112.12 | 2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $111.94 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.13 | 2023 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $90.93 | 2024 | Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $83.24 | 2023 | Rexulti |
| Dexcom, INC. | $78.03 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.54 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vapotherm INC | $66.17 | 2023 | Vapotherm |
| Biogen, INC. | $61.43 | 2024 | |
| Coloplast Corp | $56.33 | 2023 | Titan |
| Biohaven Pharmaceutical Holding Company LTD. | $24.10 | 2022 | |
| Novo Nordisk INC | $18.59 | 2023 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuela Sandoval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.